For Immediate Release
October 28, 2020
TSX/NYSE/PSE: MFC SEHK: 945
HONG KONG – Manulife Hong Kong today announced the appointment of Dr. Aggie Ngan as Chief Medical Officer, a newly created role that will enhance the company’s health offerings for customers and improve holistic customer experience through digital innovation. Dr. Ngan will drive the execution of Manulife’s health strategy and provide medical leadership and physician advice for all medical-related functions and services. She will report to Wilton Kee, Vice President, Chief Product Officer and Head of Health of Manulife Hong Kong.
“Health is a key business focus for Manulife Hong Kong and demand for protection is growing. We are investing heavily to build up our capabilities and broaden our choice of customized health solutions to serve the needs of individuals and families, employers and employees,” said Mr. Kee. “Aggie is a great addition to the Health team, bringing a wealth of medical and insurance experience that will strengthen Manulife’s position as a health expert and leader in the insurance industry.”
As Chief Medical Officer, Dr. Ngan is responsible for leading continuous improvement and establishing best practices in underwriting, claims and medical provider management. She will also pursue the development of enhanced customer journeys and work in close collaboration with operations and technology functions to identify and implement initiatives relating to claims experiences, health innovation and digitization.
Dr. Ngan is a qualified general practitioner with solid experience in the insurance industry. Prior to joining Manulife, she worked for another insurance company, with mandates to give medical advice on product features, value-added services and regulatory requirements for health initiatives, as well as providing professional training to underwriting and claims teams.
This appointment reflects Manulife’s strategic focus on its expanding health portfolio, following the establishment of a new Health function earlier this year. To meet growing demand for health protection, Manulife continues to expand its offerings, in particular with more choice of Voluntary Health Insurance Scheme (VHIS) and critical illness (CI) products. The company’s VHIS solutions are popular with customers, with sales accounting for 59% of all new medical insurance business in the first half of 2020. In July this year, Manulife refreshed its flagship CI products with the ManuBright Care 2 series that provides customers with well-rounded protection including against uncertainties arising from future unknown diseases and financial relief for post-critical illness disability care.
Dr. Aggie Ngan
Chief Medical Officer
About Manulife Hong Kong
Manulife Hong Kong, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited and Manulife Provident Funds Trust Company Limited. As a member of the Manulife group of companies, Manulife Hong Kong offers a diverse range of protection and wealth products and services to individual and corporate customers in Hong Kong and Macau.
Manulife Financial Corporation is a leading international financial services group that helps people make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across our offices in Canada, Asia, and Europe, and primarily as John Hancock in the United States. We provide financial advice, insurance, and wealth and asset management solutions for individuals, groups and institutions. At the end of 2019, we had more than 35,000 employees, over 98,000 agents, and thousands of distribution partners, serving almost 30 million customers. As of June 30, 2020, we had C$1.2 trillion (HK$6.8 trillion) in assets under management and administration, and in the previous 12 months we made C$30.6 billion in payments to our customers. Our principal operations are in Asia, Canada and the United States where we have served customers for more than 155 years. We trade as 'MFC' on the Toronto, New York, and the Philippine stock exchanges and under '945' in Hong Kong.